Near Real-Time Osteoporosis and Bone Cancer Test Developed
|
By LabMedica International staff writers Posted on 30 Aug 2015 |

Image: Photomicrograph demonstrating typical multiple myeloma histology, with monoclonal proliferation of plasma cells (Photo courtesy of Ohio State University College of Medicine).
A new test which measures changes in calcium isotope ratios offers the possibility of near real time monitoring of bone diseases, such as osteoporosis and multiple myeloma.
Bones are largely built of calcium, and the turnover of calcium can indicate the development of bone diseases such as osteoporosis and the cancer multiple myeloma and using techniques developed by geochemists it was found possible to apply them to a new, rapid test of bone health.
Scientists at Arizona State University (Tempe, AZ, USA) worked with the US National Aeronautics and Space Administration (NASA, Washington DC, USA) and measured calcium isotope ratios in urine from 30 shuttle astronauts, before, during, and after the flights. This allowed them to confirm that the test worked at high sensitivity. They also looked at a group of 71 patients who either had multiple myeloma (bone cancer), or were at risk of multiple myeloma.
The methodology used mass spectrometry and can discern the relative ratios of the calcium isotopes 42Ca and 44Ca in bone. The researchers found that lighter calcium isotopes, such as 42Ca, are absorbed from the blood into the bone during bone formation. Conversely, these light isotopes tend to be released into the bloodstream when bones break down. By measuring the ratios of the two isotopes in blood or urine scientists can calculate the rate of change of bone mass.
Ariel Anbar, PhD, the lead scientists of the study said, “What we saw with cancer patients was interesting. Those patients who tended to lose the lighter 42Ca isotope seemed to be the ones where the cancer was the most active. This means that the tests could theoretically feed into decisions on whether or not to treat a patient, for example if a cancer was dormant or growing very slowly, and to assess the effectiveness of treatments. The advantage for this methodology is that the patient doesn't have to come to the machine; the measurements can be done with a blood or urine test.”
Related Links:
Arizona State University
US National Aeronautics and Space Administration
Bones are largely built of calcium, and the turnover of calcium can indicate the development of bone diseases such as osteoporosis and the cancer multiple myeloma and using techniques developed by geochemists it was found possible to apply them to a new, rapid test of bone health.
Scientists at Arizona State University (Tempe, AZ, USA) worked with the US National Aeronautics and Space Administration (NASA, Washington DC, USA) and measured calcium isotope ratios in urine from 30 shuttle astronauts, before, during, and after the flights. This allowed them to confirm that the test worked at high sensitivity. They also looked at a group of 71 patients who either had multiple myeloma (bone cancer), or were at risk of multiple myeloma.
The methodology used mass spectrometry and can discern the relative ratios of the calcium isotopes 42Ca and 44Ca in bone. The researchers found that lighter calcium isotopes, such as 42Ca, are absorbed from the blood into the bone during bone formation. Conversely, these light isotopes tend to be released into the bloodstream when bones break down. By measuring the ratios of the two isotopes in blood or urine scientists can calculate the rate of change of bone mass.
Ariel Anbar, PhD, the lead scientists of the study said, “What we saw with cancer patients was interesting. Those patients who tended to lose the lighter 42Ca isotope seemed to be the ones where the cancer was the most active. This means that the tests could theoretically feed into decisions on whether or not to treat a patient, for example if a cancer was dormant or growing very slowly, and to assess the effectiveness of treatments. The advantage for this methodology is that the patient doesn't have to come to the machine; the measurements can be done with a blood or urine test.”
Related Links:
Arizona State University
US National Aeronautics and Space Administration
Latest Pathology News
- AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
- Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
- Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
- New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
- EBV Status Helps Predict Survival in Primary CNS Lymphoma
- AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
- AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
- 3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Channels
Molecular Diagnostics
view channel
HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
Cervical cancer is the fourth most common cancer in women and is largely preventable through vaccination and regular screening. However, even where organized screening programs exist, participation varies... Read more
Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
Hepatitis D virus infection can accelerate progression to cirrhosis and liver cancer, making timely diagnosis and longitudinal monitoring essential. Because hepatitis D depends on co-infection or superinfection... Read more
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read morePathology
view channel
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more




 Assay.jpg)



